HUGE - FSD Pharma files for starting early stage trial of multiple sclerosis drug

• FSD Pharma ( NASDAQ: HUGE ) said it submitted a clinical trial application (CTA) seeking to start a phase 1 trial of Lucid-MS to treat multiple sclerosis (MS).
• Lucid-MS is a first-in-class neuroprotective compound and in preclinical models has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases, the company added.
• "Lucid-MS is a promising first-in-class agent with a novel mechanism of action with a potential to address progressive stages of the disease," said Lakshmi Kotra, CEO of Lucid Psycheceuticals, a unit of FSD.

For further details see: